With projections that the global diabetes population will grow from 366 million currently to approximately 552 million by 2030, driven by adult-onset type 2 diabetes, biopharma deal-making in diabetes has run hot and heavy this decade. While a handful of deals centered on familiar classes of drugs such as insulin and insulin analogs, as well as DPP-4 and SGLT-2 inhibitors and GLP-1 agonists, there has been a noticeable wave of transactions around another technology – mechanisms to generate insulin-producing B cells in the pancreas.
Such technologies, including those focused on generation of pancreatic islet cells, which are formed by B cells, have been at...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?